Quest Diagnostics Reports $80,000 in Lobbying Efforts Amid Key Legislative Issues
Quest Diagnostics Incorporated recently reported spending $80,000 on lobbying during the fourth quarter of 2024, according to a new filing under the Lobbying Disclosure Act.
Key Legislative Issues Targeted in Lobbying
This lobbying effort focused on various important healthcare topics, including:
“H.R. 10545 – The Continuing Appropriations and Extensions Act, 2025” addresses federal funding for healthcare departments and seeks to delay specific cuts to laboratory payments under Medicare. Additional lobbying involves regulations relating to the FDA’s oversight of certain lab-developed tests and federally reimbursed drug testing protocols.
“H.R. 1835 – The Saving Access to Laboratory Services Act” pertains to the treatment of clinical laboratories in Medicare, regulations regarding the end of the public health emergency, and topic areas like Covid testing and sexually transmitted disease (STD) testing. Also on the docket are discussions about PFAS testing and cancer prevention initiatives, including the Cancer Moonshot program.
Other significant bills mentioned include issues relating to the syphilis crisis and support for laboratory services, particularly under “H.R. 4366 – Consolidated Appropriations and Other Extenders Act of 2024” and “H.R. 2882 – Further Consolidated Appropriations Act of 2024.”
For further information on corporate lobbying, visit Quiver Quantitative.
Insider Trading Activity at Quest Diagnostics
In the past six months, insiders at Quest Diagnostics have engaged in 14 stock transactions, with no purchases and all sales.
Here’s a closer look at recent insider trading activities:
- Michael E. Prevoznick (SVP & General Counsel): 3 trades, 0 purchases, 3 sales (67,697 shares sold).
- Catherine T. Doherty (EVP, Regional Businesses): 2 trades, 0 purchases, 2 sales (33,103 shares sold).
- Michael J. Deppe (SVP, Corp. Controller & CAO): 6 trades, 0 purchases, 6 sales (18,755 shares sold).
- Karthik Kuppusamy (SVP, Clinical Solutions): 2 trades, 0 purchases, 2 sales (3,765 shares sold).
- Mark E. Delaney (SVP & Chief Commercial Officer): sold 420 shares.
To follow insider transactions closely, check out Quiver Quantitative’s dashboard on insider trading.
Recent Hedge Fund Movements Involving DGX Stock
Recently, 368 institutional investors increased their stakes in Quest Diagnostics ($DGX), while 433 investors lowered their positions in the latest quarter.
Some notable hedge fund activities include:
- Price T Rowe Associates Inc /MD/ added 3,697,500 shares (+2381.6%) in Q3 2024.
- Marshall Wace, LLP increased their holdings by 811,640 shares (+429.4%) in Q3 2024.
- Millennium Management LLC disposed of 786,321 shares (-82.9%) in Q3 2024.
- Nuance Investments, LLC removed all 681,636 shares (-100.0%) in Q2 2024.
- American Century Companies Inc decreased shares by 564,730 (-19.8%) in Q3 2024.
- 8 Knots Management, LLC eliminated their position entirely with a reduction of 497,612 shares (-100.0%) in Q3 2024.
- Mizuho Securities USA LLC increased their stake by 442,835 shares (+5168.5%) in Q3 2024.
To keep track of hedge fund activities and stock portfolios, visit Quiver Quantitative’s institutional holdings platform.
This article does not constitute financial advice. For additional information, please refer to Quiver Quantitative’s disclaimers.
This article was originally published on Quiver News; read the complete story.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
